INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Core Insights - Ultragenyx allegedly misled investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The company is facing allegations of misleading investors about the efficacy of setrusumab in its clinical trials [1]